Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3023-3023 ◽  
Author(s):  
P. Tresca ◽  
D. Tosi ◽  
L. van Doorn ◽  
H. Fontaine ◽  
A. V. Gaast ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Advanced Solid Tumors ◽  
Vascular Disrupting Agent ◽  
Vascular Disrupting ◽  
Pharmacologic Study

scholarly journals Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

2013 ◽  
Vol 19 (17) ◽  
pp. 4832-4842 ◽  
Author(s):  
Cristiana Sessa ◽  
Patricia Lorusso ◽  
Anthony Tolcher ◽  
Françoise Farace ◽  
Nathalie Lassau ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Advanced Solid Tumors ◽  
Vascular Disrupting Agent ◽  
Vascular Disrupting

A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors

2011 ◽  
Vol 68 (4) ◽  
pp. 959-970 ◽  
Author(s):  
Alejandro D. Ricart ◽  
Edward A. Ashton ◽  
Matthew M. Cooney ◽  
John Sarantopoulos ◽  
Joanna M. Brell ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Vascular Disrupting Agent ◽  
Vascular Disrupting

scholarly journals Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors

2016 ◽  
Vol 48 (1) ◽  
pp. 28-36 ◽  
Author(s):  
Do-Youn Oh ◽  
Tae-Min Kim ◽  
Sae-Won Han ◽  
Dong-Yeop Shin ◽  
Yun Gyoo Lee ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Vascular Disrupting Agent ◽  
Vascular Disrupting

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

2012 ◽  
Vol 18 (5) ◽  
pp. 1415-1425 ◽  
Author(s):  
Dan M. Patterson ◽  
Martin Zweifel ◽  
Mark R. Middleton ◽  
Patricia M. Price ◽  
Lisa K. Folkes ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Advanced Solid Tumors ◽  
Vascular Disrupting Agent ◽  
Vascular Disrupting ◽  
Pharmacokinetic Evaluation

Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 2594-2594 ◽  
Author(s):  
M. Zweifel ◽  
D. M. Patterson ◽  
A. R. Padhani ◽  
M. R. Middleton ◽  
P. Price ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Advanced Solid Tumors ◽  
Vascular Disrupting Agent ◽  
Vascular Disrupting

A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors

2005 ◽  
Vol 57 (5) ◽  
pp. 671-677 ◽  
Author(s):  
Matthew G. Fury ◽  
Lee M. Krug ◽  
Christopher G. Azzoli ◽  
Sunil Sharma ◽  
Nancy Kemeny ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Advanced Solid Tumors ◽  
Pharmacologic Study
Sign in / Sign up

Export Citation Format

Share Document